Although the clinical success of TKIs has been dramatic, specifically for the first/second/third EGFR inhibitors, most lung cancer patients finally encounter disease progression because of various TKI resistance mechanisms [4,5,9]. This evidence concerns the gene EGFR and lung carcinoma.